5 Most Promising Micro-Cap Stocks According to Analysts

2. Atai Life Sciences N.V. (NASDAQ:ATAI)

Number of Hedge Fund Holders: 19

One-Year Average Price Target: $13.72         

Clinical-stage biopharmaceutical company Atai Life Sciences N.V. (NASDAQ:ATAI) shares took a beating in January after the company said its majority-owned unit Perception Neuroscience’s therapy PCN-101 (R-ketamine) did not meet the main goal of a Phase 2a trial for treatment-resistant depression.

However, Atai Life Sciences N.V. (NASDAQ:ATAI)’s one-year average price target of $13.72 presents a solid upside from the current levels ($1.79 as of February 14 morning).

As of the end of the third quarter of 2022, 19 hedge funds tracked by Insider Monkey reported having stakes in Atai Life Sciences N.V. (NASDAQ:ATAI). The total value of these stakes was over $53 million. The biggest stakeholder of Atai Life Sciences N.V. (NASDAQ:ATAI) during this period was Catherine D. Wood’s ARK Investment Management which had a $20.3 million stake in the company.